This cream is indicated in inflammatory dermatoses where bacterial infection is present or likely to occur. Inflammatory dermatoses include atopic eczema, discoid eczema, stasis eczema, seborrhoeic dermatitis, contact dermatitis, psoriasis and discoid lupus erythematosus.
Betamethasone & Combined preparations
Fusidic acid is only effective against gram-positive bacteria such as Streptococcus, Staphylococcus aureus and Corynebacterium minutissimum. The antibacterial action of fusidic acid results from inhibition of bacterial protein synthesis. The drug interferes with amino acid transfer from aminoacyl-tRNA to protein on the ribosomes. Betamethasone induces lipocortin which inhibits phospholipase A-2 enzyme which results in the inhibition of different inflammartory mediators synthesis like prostaglandins, cinins, histamines.
Pharmacokinetics: Fusidic acid can penetrate intact human skin. As much as 2% of the amount of topically applied fusidic acid penetrates intact skin. The degree of penetration depends on factors such as the duration of exposure to fusidic acid and the condition of the skin. Fusidic acid is excreted mainly in the bile with little excreted in the urine. Dermal absorption and potency of any topical corticosteroid including betamethasone depends on the vehicle in which the steroid is delivered. Absorption of betamethasone may be higher in certain body areas such as the face, groin, axilla, or on injured or inflamed skin such as the lesions of atopic dermatitis.
Uncovered lesions: 2-3 times daily applications. Covered lesions: Less frequent application may be adequate.
Other topical (skin-applied) medications contain corticosteroids.
Topical corticosteroids are contraindicated in viral, tuberculous and fungal skin infections, perioral dermatitis, acne rosacea and ulcerative condition. Also contraindicated in case of hypersensitivity to any component. May increase risk of developing antibiotic resistance. Stasis dermatitis and other skin disease with impaired circulation. Not to be used for >7 days if there is no clinical improvement. Avoid prolonged continuous treatment especially in infants and children, Pregnancy and lactation.
Hypersensitivity, contact dermatitis, eczema (aggravated condition), skin burning sensation, pruritus, dry skin, application site pain or irritation. Rarely, erythema, urticaria (including rash erythematous and generalised rash), application site swelling or vesicles.
Pregnancy Category-Not Classified. FDA has not yet classified the drug into a specified pregnancy category.
Keep out of reach of children. Store in a dry place, below 25˚C temperature and protected from light.
.png&w=384&q=75)